LENSAR reports FY2025 revenue $58.4M, recurring revenue $46.3M and 79% recurring mix
I'm LongbridgeAI, I can summarize articles.LENSAR reported FY2025 revenue of $58.4 million, with recurring revenue of $46.3 million, making up 79% of total revenue. The company experienced a net loss of $34.3 million for the year. The ALLY system adoption is accelerating, with an installed base of approximately 200 systems, a 48% increase from the previous year. Procedure volume rose by 22% to 206,014 in 2025. LENSAR has terminated its merger with Alcon and will independently commercialize the ALLY Robotic Laser Cataract System.
LENSAR reported total revenue of $58.4 million for the year ended December 31, 2025, with recurring revenue of $46.3 million representing 79% of full-year revenue. The company posted a fourth-quarter net loss of $1.5 million (‑$0.12 per share) and full-year net loss of $34.3 million (‑$2.87 per share). Management highlighted accelerating ALLY system adoption and growing procedure volume while transitioning to an independent go-forward strategy after termination of the previously contemplated merger.
Financial Highlights
- Total revenue for FY2025: $58,435 thousand.
- Recurring revenue for FY2025: $46,306 thousand (79% of total revenue for both Q4 and FY2025).
- Fourth-quarter total revenue: $16,025 thousand; fourth-quarter recurring revenue: $12,650 thousand.
- Net loss: Q4 2025 net loss $(1,458) thousand (basic and diluted loss per share $0.12); FY2025 net loss $(34,280) thousand (basic and diluted loss per share $2.87).
- Adjusted EBITDA: Q4 2025 $595 thousand; FY2025 Adjusted EBITDA $208 thousand.
Business Highlights
- ALLY installed base expanded to approximately 200 systems at year-end 2025, a 48% increase over December 31, 2024, with 15 ALLY Systems placed in Q4 2025 and a backlog of 13 pending installations as of year-end.
- Total combined installed base of LENSAR Laser Systems and ALLY Systems grew to ~435 systems as of December 31, 2025, up 13% year-over-year.
- Worldwide procedure volume for 2025 increased to 206,014 procedures, a 22% increase compared to 2024, with Q4 procedure volume up ~20% year-over-year.
- Recurring revenue drivers included procedure, lease and service streams; procedure revenue for FY2025 was $33.8 million, supporting the recurring revenue mix and utilization growth across the installed base.
- Company executed a Termination and Mutual Release Agreement with Alcon on March 18, 2026, will retain the $10.0 million merger deposit and is moving forward independently with commercialization of the ALLY Robotic Laser Cataract System.
Original SEC Filing: LENSAR, Inc. [ LNSR ] - 8-K - Mar. 31, 2026